

**POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO**

I hereby revoke all previous powers of attorney given in the applications identified in the attached **Schedule A**.

I hereby appoint:

☒ Practitioners associated with the Customer Number: **86738**

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: **86738**

OR

☐ Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Email


Assignee Name and Address:

Ziopharm Oncology, Inc.  
1 First Avenue  
Parris Building, #34  
Navy Yard Plaza  
Boston, MA 02129

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

**SIGNATURE of Assignee of Record**

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	<b>22 OCT 2012</b>
Name	<b>Caesar J. Belbel</b>	Telephone	<b>017-251-1970</b>
Title	<b>EVP &amp; Chief Legal Officer, Ziopharm Oncology, Inc.</b>		

PTO/SB/80 (11-08)

Approved for use through 11/30/2011. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# SCHEDULE A

Appln. No.	Filing Date	1 <sup>st</sup> Inventor	Title	Ziopharm No.	McCarter No.
08/925326	09/08/1997	LEBAUT, Guillaume	N-SUBSTITUTED INDOL-3-GLYOXYLAMIDES HAVING ANTI-ASTHMATIC ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNO-MODULATING ACTION	ZIPH 007.1US	121840-00701
09/409263	09/30/1999	LEBAUT, Guillaume	N-SUBSTITUTED INDOLE-3-GLYOXYLAMIDES HAVING ANTI-ASTHMATIC ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNO-MODULATING ACTION	ZIPH 007.1USD1	121840-00703
10/402931	04/01/2003	LEBAUT, Guillaume	N-SUBSTITUTED INDOLE-3-GLYOXYLAMIDES HAVING ANTI-ASTHMATIC ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNO-MODULATING ACTION	ZIPH 007.1USD2CN	121840-00705
09/285058	04/02/1999	NICKEL, Bernd	INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING ANTITUMOR ACTION	ZIPH 008.1US	121840-00801
10/309204	12/04/2002	NICKEL, Bernd	INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING ANTITUMOR ACTION	ZIPH 008.1USC2	121840-00803
09/492531	01/27/2000	NICKEL, Bernd	INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE PROPERTIES	ZIPH 009.1US	121840-00901
10/686809	10/17/2003	NICKEL, Bernd	INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE PROPERTIES	ZIPH 009.1USCN	121840-00902
11/266518	11/03/2005	PAPADOPOU LOS, Pavlos	NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR COMPOUNDS	ZIPH 028.1US	121840-02803